A study on immunity after Covid 19 vaccine

Not Applicable

Registration Number: CTRI/2021/07/034663

Lead Sponsor: ational Centre for Biological Science

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Permanent residents of the selected localities where community outreach is routine

- Only one member from a household will be selected.

- Either a) sero-negativity or b) sero-positivity to SARS-CoV-2 with or without a history of clinical illness suggestive of COVID-19 or confirmed COVID-19 in the past (either mild or moderate infection)

Exclusion Criteria

- Participant failure to consent.

- Pregnancy, diabetes, chronic infection such as HIV or tuberculosis and immunocompromised patients (all by history)

- Acute febrile illness in the participant at the time of the survey.

- Active cancers or bleeding disorders

- Individuals with a history of severe COVID-19 that required ventilation or received either convalescent plasma or monoclonal antibody treatments.

- Any medical condition in the participant, which, in the judgment of the investigator, would interfere with protocol adherence.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- Difference in titers and rate of increase of plasma neutralizing antibody/glycoprotein-specific antibodies post vaccination between individuals seropositive and seronegative at baseline <br/ ><br> <br/ ><br>- Magnitude of binding antibody titers (RBD/spike, nucleocapsid) post vaccination in individuals seropositive and seronegative at baseline <br/ ><br> <br/ ><br>- Seroconversion rate and duration of antibodies in individuals sero-negative at baseline <br/ ><br> <br/ ><br>Timepoint: day 42 90 180 270

Secondary Outcome Measures

Name	Time	Method
Difference in frequency of RBD/spike-reactive memory B cells post-vaccination between individuals seropositive and seronegative at baseline <br/ ><br> <br/ ><br>-Difference in positivity and magnitude of cytokine-producing T cells against spike peptides between individuals seropositive and seronegative at baselineTimepoint: day 42 90 180 270